Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report
Thoracic Cancer · 2025-01 · 16 (2)
DOI: 10.1111/1759-7714.15519 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, online erschienen am 17.12.2024. Verfasst von Yugo Matsumura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi City, Kochi, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lung Neoplasms, Carcinoma, Squamous Cell, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We herein describe a patient with non‐small‐cell lung cancer who achieved pCR with a single dose of pembrolizumab‐based chemoimmunotherapy followed by surgery. A 61‐year‐old man was referred to our hospital with wheezing and an abnormal chest shadow. Squamous cell carcinoma of the left lower lobe, cT2aN1M0 stage IIB, was diagnosed and pembrolizumab‐based chemoimmunotherapy was initiated at the patient's request. One month later, chest CT revealed new ground‐glass opacities of the lungs, which were judged to be a CTCAE grade 2 pneumonitis due to an immune‐related adverse event (irAE). Therefore, steroid therapy was initiated. Prednisolone was tapered and discontinued as symptoms improved. A sleeve resection of the left lower lobe was performed, and a pathological complete response (pCR) was confirmed in a resected specimen. There has been no recurrence for 1 year and 7 months without treatment. This is the first case report of pCR to a single dose of chemoimmunotherapy followed by surgery for lung cancer. The present results suggest the potential of a single dose of chemoimmunotherapy to achieve pCR and cause irAEs in some patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi City, Kochi, Japan.
- Department of Thoracic Surgery, National Hospital Organization Kochi Hospital, Kochi City, Kochi, Japan.
- Department of Pathology, National Hospital Organization Kochi Hospital, Kochi City, Kochi, Japan.
- Department of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
- Department of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi City, Kochi, Japan.
ORCID-Profile: Eiji Takeuchi
Zitieren
APA
Matsumura, Y., Ichihara, S., Nii, K., Nanjo, K., Kadota, N., Okano, Y., Machida, H., Hatakeyama, N., Hino, H., Naruse, K., Shinohara, T., Sakiyama, S., & Takeuchi, E. (2025). Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report. Thoracic Cancer, 16(2). https://doi.org/10.1111/1759-7714.15519
Vancouver
Matsumura Y, Ichihara S, Nii K, Nanjo K, Kadota N, Okano Y, et al. Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report. Thoracic Cancer. 2025;16(2). doi:10.1111/1759-7714.15519
BibTeX
@article{Matsumura2025,
author = {Matsumura, Yugo and Ichihara, Seiya and Nii, Kaori and Nanjo, Kazumasa and Kadota, Naoki and Okano, Yoshio and Machida, Hisanori and Hatakeyama, Nobuo and Hino, Hiroyuki and Naruse, Keishi and Shinohara, Tsutomu and Sakiyama, Shoji and Takeuchi, Eiji},
title = {Pathological Complete Response to a Single Dose of Pembrolizumab‐Based Chemoimmunotherapy for Squamous Cell Carcinoma of the Lung: A Case Report},
journal = {Thoracic Cancer},
year = {2025},
volume = {16},
number = {2},
doi = {10.1111/1759-7714.15519}
}
EUVIMED